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Introduction 
• Calcitriol and its 1α-hydroxylated analogs frequently increase serum 
calcium (Ca) and the risk of vascular calcification in patients with stage 
3-4 CKD. For this reason, the revised KDIGO Guideline for CKD-MBD 
suggests that these agents not be routinely used in this population.1 
• Secondary hyperparathyroidism (SHPT) is commonly associated with 
CKD as a result of vitamin D insufficiency (VDI) and other factors.2,3 
• Randomized clinical trials (RCTs) with oral extended-release calcifediol 
(ERC), an FDA-approved therapy for SHPT, demonstrated effective 
control of elevated plasma intact parathyroid hormone (iPTH) with 
minimal changes in serum Ca in stage 3-4 CKD.4 
• Data from these RCTs were examined post-hoc to assess the potential 
impact of baseline serum Ca on end-of-treatment (EOT) serum Ca, 
phosphorus (P), total 25-hydroxyvitamin D (25D) and total 1,25-
dihydroxyvitamin D (1,25D), and on plasma iPTH in ERC- and placebo-
treated subjects.  
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Methods 
• This was a post-hoc analysis of pooled data from 2 identical, 
randomized, multisite, double-blind, placebo-controlled 26-week trials in 
429 subjects. 
• Eligible subjects had stage 3 or 4 CKD, SHPT, and VDI; were aged ≥18 
years, with urinary albumin excretion ≤3000 mcg/mg creatinine (Cr); 
estimated glomerular filtration rate ≥15–<60 mL/min/1.73 m2, plasma 
iPTH >85–<500 pg/mL; serum Ca ≥8.4–<9.8 mg/dL; serum P ≥2.0–
<5.0 mg/dL; serum 25D ≥10–<30 ng/mL; elemental Ca intake ≤1000 
mg/day and vitamin D intake ≤1600 IU/day; and spot urine Ca:Cr ratio 
≤0.2 (≤200 mg/g).  
• Subjects were randomized in a 2:1 ratio to receive oral once-daily 
bedtime doses of ERC (30 mcg) or placebo. 
– The ERC dose was increased to 60 mcg daily at Week 13 in 
subjects with serum 25D <65 ng/mL, serum Ca <9.8 mg/dL, and 
plasma iPTH >70 pg/mL (averaged over weeks 8–10).  
• Post-hoc analyses were conducted of per-protocol data on the 
comparative efficacy of ERC vs placebo for increasing serum total 25D 
and reducing iPTH. 
• Time course data for the per-protocol ERC and placebo populations 
were ranked by baseline serum Ca and divided into tertiles. Selected 
data for each tertile are presented for three time points (baseline, 
Week12 and EOT) along with mean changes from baseline, by 
treatment group. EOT was defined as the Efficacy Assessment Period 
(EAP, mean of weeks 20-26). 
• Statistical differences between placebo - and ERC-treated subjects for 
each tertile, at baseline and for changes from baseline,  were assessed 
by t-test. 
Results 
Table 1. Subject demographics at baseline 
1,25D, 1,25-dihydroxyvitamin D; 25D, 25-hydroxyvitamin D; BMI, body mass index; eGFR, estimated glomerular filtration rate;  
iPTH, intact parathyroid hormone; SE, standard error.  
Conclusions 
• ERC treatment effectively increased mean serum total 25D and 1,25D, 
and reduced mean plasma iPTH, in all tertiles. 
• Baseline serum Ca affected serum 1,25D and plasma iPTH responses to 
ERC treatment. ERC-induced increases in 1,25D and decreases in iPTH 
were greatest in subjects with the lowest baseline Ca. 
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Objective 
• The objective of this analysis was to determine the impact of 
baseline serum Ca on EOT parameters in patients with stage 3-4 
CKD. 
Figure 1. Changes in mean serum Ca 
Figure 2. Changes in mean serum P 
Figure 5. Changes in mean serum total 1,25D 
Figure 4. Changes in mean plasma iPTH 
Placebo ERC 
Variable 
Tertile 1  
n (%) 




Tertile 1  
n (%) 




Number of subjects 41 40 41 78 78 78 
Gender 
    Female 15 23 22 29 42 47 
    Male 26 17 19 49 36 31 
Tertile 1  
Mean (SE) 




Tertile 1  
Mean (SE) 




Weight, kg 98.0 (3.3) 92.1 (3.3) 99.6 (3.8) 98.0 (2.6) 96.3 (3.0) 101.0 (3.0) 
BMI , kg/m2 34.9 (1.2) 34.0 (1.2) 34.8 (1.2) 33.6 (0.8) 34.4 (0.9) 36.5 (1.0) 
Age, y 62.2 (1.8) 67.3 (1.8) 63.0 (1.8) 66.4 (1.2) 65.8 (1.3) 65.8 (1.1) 
Serum Ca, mg/dL 8.9 (0.02) 9.3 (0.01) 9.5 (0.02) 8.9 (0.02) 9.2 (0.01)** 9.5 (0.02) 
Serum P, mg/dL 3.7 (0.1) 3.7 (0.1) 3.7 (0.1) 3.8 (0.1) 3.7 (0.1) 3.7 (0.1) 
Total 25D, ng/mL 19.5 (0.9) 20.1 (1.0) 18.2 (0.8) 19.8 (0.6) 19.2 (0.6) 20.2 (0.6)* 
Total 1,25D (pg/mL) 37.5 (2.8) 34.4 (1.9) 36.0 (2.0) 32.3 (1.5) 33.9 (1.5) 37.2 (1.5) 
iPTH, pg/mL 146.5 (7.1) 148.5 (10.8) 140.8 (5.6) 156.5 (5.5) 138.4 (6.9) 136.0 (6.9) 
eGFR, mL/min/1.73 
m2 






















































































Tertile 1                         Tertile 2                          Tertile 3 
*  Significantly different from placebo, p < 0.05 
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ERC 

























































































Tertile 1                         Tertile 2                  Tertile 3 





















































































Tertile 1                         Tertile 2                    Tertile 3 
**    Significantly different from placebo, p < 0.01 







































**    Significantly different from placebo, p < 0.01 
***  Significantly different from placebo, p < 0.001 


























































Low                     Medium                     High 
ERC 
• Significant differences in baseline demographic characteristics between 
active and placebo subjects in each tertile are as marked (Table 1). More 
men were included in Tertile 1 and more women in Tertiles 2 and 3. 
Plasma iPTH trended higher with decreasing baseline serum Ca. 
• Mean serum Ca levels (Figure 1) increased with ERC treatment in all 
tertiles (p < 0.05 or less), with greater changes at lower baseline Ca. 
• Mean serum P (Figure 2) was not significantly affected by ERC treatment, 
relative to placebo (p = ns). 
• Mean serum 25D (Figure 3) increased similarly with ERC treatment in all 
tertiles (p < 0.0001). 
• Mean plasma iPTH (Figure 4) decreased with ERC treatment in all tertiles, 
with greater changes at lower baseline serum Ca (p < 0.01 or p < 0.0001). 
• ERC treatment increased mean serum 1,25D in all tertiles (Figure 5), with 
levels converging at EOT and larger increases at lower baseline serum Ca 
(p < 0.01 or less). 
 
